XML 47 R31.htm IDEA: XBRL DOCUMENT
v3.25.2

Derivative Liability (Tables) | 6 Months Ended | 12 Months Ended
--- | --- | ---
Jun. 30, 2025 | Dec. 31, 2024
Schedule of Derivative Warrant Liabilities | The key inputs for the Series A warrant liabilities were as follows: Schedule of Derivative Warrant Liabilities
Warrant Liability – Series A Warrants |  | January 17, 2025 |  |  | December 31, 2024 |
Stock price on valuation date |  | $ | 8.38 |  |  | $ | 18.00 |
Exercise price |  | $ | 8.38 |  |  | $ | 34.00 |
Number of warrants |  |  | 1,133,652 |  |  |  | 279,412 |
Remaining term (years) |  |  | 4.88 |  |  |  | 4.93 |
Annual equity volatility |  |  | 126.0 | % |  |  | 113.0 | %
Annual volume volatility |  |  | 377.0 | % |  |  | 379.0 | %
Risk-free interest rate |  |  | 4.32 | % |  |  | 4.29 | %
Expected stockholder approval date |  |  | January 13, 2025 |  |  |  | January 14, 2025 |
Expected stockholder approval probability |  |  | 100 | % |  |  | 50 | %
Schedule of fair value of the Derivative Liabilities | The following table provides a roll-forward of the fair value of the derivative liabilities described above during the six months ended June 30, 2025: Schedule of Fair Value of the Derivative Liabilities
|  | Series A Warrants |  |  | Series B Warrants |  |  | Total Warrant Liabilities |
Balance at December 31, 2024 |  | $ | 5,456,000 |  |  | $ | 11,147,000 |  |  | $ | 16,603,000 |
Balance |  | $ | 5,456,000 |  |  | $ | 11,147,000 |  |  | $ | 16,603,000 |
Exercises |  |  | — |  |  |  | (15,214,000 | ) |  |  | (15,214,000 | )
Loss on change in fair value |  |  | 2,401,000 |  |  |  | 4,067,000 |  |  |  | 6,468,000 |
Reclassification to equity |  |  | (7,857,000 | ) |  |  | — |  |  |  | (7,857,000 | )
Balance at June 30, 2025 |  | $ | — |  |  | $ | — |  |  | $ | — |
Balance |  | $ | — |  |  | $ | — |  |  | $ | — |
Schedule of Shares of Common Stock Underlying Warrants | The following table provides a roll-forward of the number of shares of common stock underlying warrants issued during the six months ended June 30, 2025: Schedule of Shares of Common Stock Underlying Warrants
|  | Series A Warrants |  |  | Series B Warrants |  |  | Other Warrants |  |  | Total |
Balance at December 31, 2024 |  |  | 279,412 |  |  |  | 279,412 |  |  |  | 4,511 |  |  |  | 563,335 |
Balance |  |  | 279,412 |  |  |  | 279,412 |  |  |  | 4,511 |  |  |  | 563,335 |
Exercises |  |  | — |  |  |  | (279,412 | ) |  |  | — |  |  |  | (279,412 | )
Balance at June 30, 2025 |  |  | 279,412 |  |  |  | — |  |  |  | 4,511 |  |  |  | 283,923 |
Balance |  |  | 279,412 |  |  |  | — |  |  |  | 4,511 |  |  |  | 283,923 |
Previously Reported [Member] |  |
Schedule of Derivative Warrant Liabilities |  | Schedule of Derivative Warrant Liabilities
Warrant Liability – Series A Warrants |  | Issuance Date |  |  | December 31, 2024 |
Stock price on valuation date |  | $ | 18.00 |  |  | $ | 18.00 |
Exercise price |  | $ | 34.00 |  |  | $ | 34.00 |
Number of warrants |  |  | 279,412 |  |  |  | 279,412 |
Remaining term (years) |  |  | 5.00 |  |  |  | 4.93 |
Annual equity volatility |  |  | 113.0 | % |  |  | 114.0 | %
Annual volume volatility |  |  | 377.0 | % |  |  | 379.0 | %
Risk-free interest rate |  |  | 3.95 | % |  |  | 4.29 | %
Expected stockholder approval date |  |  | January 14, 2025 |  |  |  | January 14, 2025 |
Expected stockholder approval probability |  |  | 50 | % |  |  | 50 | %
ALGORHYTHM HOLDINGS, INC AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023
Warrant Liability – Series B Warrants |  | Issuance Date |  |  | December 31, 2024 |
Stock price on valuation date |  | $ | 18.00 |  |  | $ | 18.00 |
Exercise price |  | $ | 68.00 |  |  | $ | 68.00 |
Number of warrants |  |  | 279,412 |  |  |  | 279,412 |
Remaining term (years) |  |  | 2.50 |  |  |  | 2.43 |
Annual equity volatility |  |  | 126.0 | % |  |  | 120.0 | %
Annual volume volatility |  |  | 409.0 | % |  |  | 416.0 | %
Risk-free interest rate |  |  | 4.00 | % |  |  | 4.17 | %
Expected stockholder approval date |  |  | January 14, 2025 |  |  |  | January 14, 2025 |
Expected stockholder approval probability |  |  | 50 | % |  |  | 50 | %
Schedule of fair value of the Derivative Liabilities |  | The following table provides a roll-forward of the fair value of the derivative liabilities described above: Schedule of fair value of the Derivative Liabilities
|  | Series A Warrants |  |  | Series B Warrants |  |  | Total Warrant Liabilities |
Balance at December 31, 2023 |  | $ | — |  |  | $ | — |  |  | $ | — |
Issuances |  |  | 5,901,000 |  |  |  | 11,036,000 |  |  |  | 16,937,000 |
Exercises |  |  | — |  |  |  | — |  |  |  | — |
Loss (gain) on change in fair value |  |  | (445,000 | ) |  |  | 111,000 |  |  |  | (334,000 | )
Balance at December 31, 2024 |  | $ | 5,456,000 |  |  | $ | 11,147,000 |  |  | $ | 16,603,000 |
Schedule of Shares of Common Stock Underlying Warrants |  | The following table provides a roll-forward of the number of shares of common stock underlying warrants issued during the year ended December 31, 2024 and the nine months ended December 31, 2023: Schedule of Shares of Common Stock Underlying Warrants
|  | Pre-Funded Warrants |  |  | Series A Warrants |  |  | Series B Warrants |  |  | Other Warrants |  |  | Total |
Balance at March 31, 2023 |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 4,511 |  |  |  | 4,511 |
Issuances |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Exercises |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Balance at December 31, 2023 |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 4,511 |  |  |  | 4,511 |
Issuances |  |  | 258,412 |  |  |  | 279,412 |  |  |  | 279,412 |  |  |  | — |  |  |  | 817,236 |
Exercises |  |  | (258,412 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (258,412 | )
Balance at December 31, 2024 |  |  | — |  |  |  | 279,412 |  |  |  | 279,412 |  |  |  | 4,511 |  |  |  | 563,335 |
Schedule of fair value on a recurring basis |  | The following table details the Company’s financial instruments that are required to be remeasured at fair value on a recurring basis and their fair value hierarchy as of December 31, 2024: Schedule of fair value on a recurring basis
December 31, 2024 |  | Level 1 |  |  | Level 2 |  |  | Level 3 |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |
Warrant liabilities |  | $ | — |  |  | $ | — |  |  | $ | 16,603,000 |
Total liabilities |  | $ | — |  |  | $ | — |  |  | $ | 16,603,000 |

X
- Definition Tabular disclosure of derivative liabilities at fair value. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4E -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details
Name: | us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details
Name: | us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |